Biologic Rationale And Evidence
Pycnogenol® is a patented extract of bark from the French maritime pine tree, Pinus pinaster, subspecies Atlanticus des Villar. Ingestion and topical application of pine bark and needle preparations for medicinal purposes dates back several centuries, with the first described use by the French explorer Jacques Cartier as a remedy for his scurvy afflicted crew on the St Lawrence River near Quebec in 15351. Nearly four centuries later, the French researcher, Jacques Masquelier isolated an ascorbate-enhancing flavanol (polyphenolic antioxidant containing catechins) he called oligoprocyanidin2 (OPC) from French Maritime Pine and patented the extraction process, later dubbing the end product Pycnogenol®.
Glaucoma is a multifaceted disorder as described in the up-coming series…Challenging the Glaucoma Archetype in eyelessons.com. The standard methods of treatment revolve around lowering the IOP to an acceptable range….whatever that may be. That pressure-lowering approach is a paradigm that really does not recognize all of the components of the glaucoma issues yet it remains the standard of care. The glaucoma concept as a systemic disorder is addressed in the companion piece in eyelessons.com but the topic of Mirtogenol™ deserves a separate highlight. Mirtogenol™ is a supplement that has been suggested as being potentially beneficial in the management of glaucoma. This is a report of this product and should neither be considered an endorsement nor an encouragement to prescribe.